Product Reports Resources Pricing Login Book a demo

PhaseV

Biotech & Life Sciences · Tel Aviv-Yafo, Israel · Founded 2023

Uses advanced algorithms to optimize clinical trials, improving success rates, efficiency, and uncovering hidden signals in the data MoreLess

PhaseVTrials.com is a cutting-edge startup that specializes in developing a platform for adaptive clinical trial design and execution. The company leverages advanced technologies such as reinforcement learning and causal machine learning (ML) to optimize clinical decisions at any stage of the trial process. Their platform features an intuitive user interface and a flexible software architecture, making it accessible and adaptable for various clinical needs.

PhaseVTrials primarily serves pharmaceutical companies, biotech firms, and research institutions that are involved in drug development and clinical research. The market it operates in is the clinical trials sector, which is a critical component of the broader healthcare and pharmaceutical industries.

The business model of PhaseVTrials revolves around providing a software-as-a-service (SaaS) platform. Clients subscribe to their platform to design, manage, and execute clinical trials more efficiently. The company generates revenue through subscription fees, which can be tiered based on the level of service and features required by the client. Additionally, they may offer consulting services to help clients optimize their trial designs and execution strategies.

PhaseVTrials stands out in the market by offering a unique combination of advanced algorithms and user-friendly software. This allows clients to make data-driven decisions, potentially reducing the time and cost associated with bringing new drugs to market. The platform's ability to adapt and provide real-time insights is particularly valuable in the fast-paced and highly regulated environment of clinical trials.

In summary, PhaseVTrials.com is revolutionizing the clinical trial process with its adaptive design and execution platform, serving pharmaceutical and biotech companies with a SaaS business model that leverages advanced algorithms for optimal decision-making.

Keywords: adaptive clinical trials, reinforcement learning, causal ML, SaaS, pharmaceutical, biotech, drug development, user interface, software architecture, data-driven decisions.

Valuation $250–500M
Revenue $1–10M
Headcount <100
Total funding $50–100M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for PhaseV and the history behind them.

Talent graph

PhaseV's talent

Book a demo to see the people
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

5 investors on PhaseV's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage

Global footprint

Where PhaseV has talent and traffic

Workforce by country
4 countries with
team presence
🇮🇱 Israel63.5%
🇺🇸 United States32.7%
🇳🇱 Netherlands1.9%
🇬🇧 United Kingdom1.9%
4 countries shown

Market sentiment

What the market is saying about PhaseV

An AI-synthesized read of the highest-engagement posts about PhaseV on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See PhaseV on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.